{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:50:45Z","timestamp":1789962645441,"version":"4.0.1"},"reference-count":30,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2009,3,31]],"date-time":"2009-03-31T00:00:00Z","timestamp":1238457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2009,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Posttraumatic stress disorder (PTSD) is a disabling psychiatric disorder that is common among combat veterans and may lead to very poor sleep and disturbing nightmares.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To examine the safety and effectiveness of topiramate as add-on therapy for the management of combat-related PTSD and to examine the effects of topiramate on sleep and alcohol consumption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted an 8-week open-label pilot study of topiramate (or male combat veterans (N = 43) with PTSD, with analysis of veterans who completed the protocol. Psychometric, sleep, and alcohol consumption assessments were conducted at baseline and at week 8.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Twenty-nine subjects completed the 8-week study. Significant reductions in Clinician Administered PTSD Scale scores were observed at the 8-week endpoint (from 86,3 \u00b1 21.1 to 67.1 \u00b1 25.1; p &lt; 0.01). Decreases were seen in both Stanford Sleepiness Scale scores (from 10.5 \u00b1 0.72 to 9.0 \u00b1 0.58; p = 0.08) and Mississippi PTSD scores (from 120.4 \u00b1 6.5 to 111.5 \u00b1 20.9; p = 0.08), but the extent of the changes did not attain statistical significance for either scale. There was a significant reduction in the proportion of patients with nightmares (from 100% to 62%; p &lt; 0.001) and patients who experienced anxiety that interfered with falling asleep (from 90% to 62%; p &lt; 0.05). The proportion of patients with high-risk drinking patterns also decreased (from 31% to 14%). Two serious adverse events were reported during the study: an increase in tow back pain and an episode of acute confusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>When used in addition to other empiric therapy, topiramate may be effective at reducing general symptoms of combat-related PTSD and reducing high-risk alcohol intake and nightmares. Further randomized controlled trials of topiramate for the treatment of combat-related PTSD are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1l578","type":"journal-article","created":{"date-parts":[[2009,3,31]],"date-time":"2009-03-31T22:00:14Z","timestamp":1238536814000},"page":"635-641","source":"Crossref","is-referenced-by-count":36,"title":["Topiramate in Combat-Related Posttraumatic Stress Disorder"],"prefix":"10.1177","volume":"43","author":[{"given":"Christopher P","family":"Alderman","sequence":"first","affiliation":[{"name":"Pharmacy Department, Repatriation General Hospital, Adelaide, South Australia; Associate Professor, Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Adelaide, South Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda C","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Post Traumatic Stress Disorder Unit, Repatriation General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T","family":"Condon","sequence":"additional","affiliation":[{"name":"FRANZCP, Senior Consultant Psychiatrist, Repatriation General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita C","family":"Marwood","sequence":"additional","affiliation":[{"name":"Senior Clinical Pharmacist, Repatriation General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith R","family":"Fuller","sequence":"additional","affiliation":[{"name":"Post Traumatic Stress Disorder Unit, Repatriation General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2009,3,31]]},"reference":[{"key":"bibr1-aph.1L578","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2007.tb01158.x"},{"key":"bibr2-aph.1L578","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/25.2.331"},{"key":"bibr3-aph.1L578","volume-title":"ABS: mental health and wellbeing: profile of adults, Australia 1997","author":"McLennan W","year":"1998"},{"key":"bibr4-aph.1L578","first-page":"CD003388","author":"Bisson J","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr5-aph.1L578","first-page":"CD002795","author":"Stein DJ","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr6-aph.1L578","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464040-00004"},{"key":"bibr7-aph.1L578","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.2.371"},{"key":"bibr8-aph.1L578","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0208"},{"key":"bibr9-aph.1L578","first-page":"565","volume":"63","author":"Raskind MA","year":"2002","journal-title":"Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder J Clin Psychiatry"},{"key":"bibr10-aph.1L578","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-198909000-00005"},{"key":"bibr11-aph.1L578","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0104"},{"issue":"17","key":"bibr12-aph.1L578","first-page":"60","volume":"62","author":"Berlant JL","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"bibr13-aph.1L578","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-4-24"},{"key":"bibr14-aph.1L578","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0204"},{"key":"bibr15-aph.1L578","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-007-0035-5"},{"key":"bibr16-aph.1L578","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.4501006.x"},{"key":"bibr17-aph.1L578","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb02165.x"},{"key":"bibr18-aph.1L578","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb02164.x"},{"key":"bibr19-aph.1L578","first-page":"240","volume":"9","author":"Akuchekian S","year":"2004","journal-title":"J Res Med Sci"},{"key":"bibr20-aph.1L578","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0b013e31815a43ee"},{"key":"bibr21-aph.1L578","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2007.11.001"},{"key":"bibr22-aph.1L578","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.14.1641"},{"key":"bibr23-aph.1L578","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"bibr24-aph.1L578","doi-asserted-by":"publisher","DOI":"10.1002\/jts.2490080106"},{"key":"bibr25-aph.1L578","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.56.1.85"},{"key":"bibr26-aph.1L578","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8986.1973.tb00801.x"},{"key":"bibr27-aph.1L578","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1993.tb00822.x"},{"key":"bibr28-aph.1L578","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1993.tb02093.x"},{"key":"bibr29-aph.1L578","volume-title":"Australian alcohol guidelines: health risks and benefits","author":"National Health and Medical Research Council.","year":"2001"},{"key":"bibr30-aph.1L578","volume-title":"Guidelines on the reporting of adverse drug reactions by drug sponsors","year":"2007"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1L578","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1L578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:06:27Z","timestamp":1777374387000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1L578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,31]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["10.1345\/aph.1L578"],"URL":"https:\/\/doi.org\/10.1345\/aph.1l578","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,31]]}}}